ATE355289T1 - 1-(aminoalkyl)-3-sulfonylazaindole als 5- hydroxytryptamin-6 liganden - Google Patents
1-(aminoalkyl)-3-sulfonylazaindole als 5- hydroxytryptamin-6 ligandenInfo
- Publication number
- ATE355289T1 ATE355289T1 AT03734366T AT03734366T ATE355289T1 AT E355289 T1 ATE355289 T1 AT E355289T1 AT 03734366 T AT03734366 T AT 03734366T AT 03734366 T AT03734366 T AT 03734366T AT E355289 T1 ATE355289 T1 AT E355289T1
- Authority
- AT
- Austria
- Prior art keywords
- sulfonylazaindole
- hydroxytryptamine
- aminoalkyl
- ligands
- Prior art date
Links
- 239000003446 ligand Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- C07D519/04—Dimeric indole alkaloids, e.g. vincaleucoblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Steroid Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38550202P | 2002-06-04 | 2002-06-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE355289T1 true ATE355289T1 (de) | 2006-03-15 |
Family
ID=29712180
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03734366T ATE355289T1 (de) | 2002-06-04 | 2003-06-03 | 1-(aminoalkyl)-3-sulfonylazaindole als 5- hydroxytryptamin-6 liganden |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | US6825212B2 (de) |
| EP (1) | EP1509522B1 (de) |
| JP (1) | JP2005532349A (de) |
| KR (1) | KR20050013565A (de) |
| CN (1) | CN1315827C (de) |
| AR (1) | AR040047A1 (de) |
| AT (1) | ATE355289T1 (de) |
| AU (1) | AU2003239954A1 (de) |
| BR (1) | BR0311591A (de) |
| CA (1) | CA2486191A1 (de) |
| DE (1) | DE60312155T2 (de) |
| DK (1) | DK1509522T3 (de) |
| EC (1) | ECSP045474A (de) |
| ES (1) | ES2282637T3 (de) |
| IL (1) | IL165487A0 (de) |
| MX (1) | MXPA04011331A (de) |
| NO (1) | NO20044763L (de) |
| NZ (1) | NZ536959A (de) |
| PT (1) | PT1509522E (de) |
| RU (1) | RU2315048C2 (de) |
| SI (1) | SI1509522T1 (de) |
| TW (1) | TW200408638A (de) |
| UA (1) | UA78999C2 (de) |
| WO (1) | WO2003101990A1 (de) |
| ZA (1) | ZA200500022B (de) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7632955B2 (en) | 2001-12-13 | 2009-12-15 | National Health Research Institutes | Indole compounds |
| US7528165B2 (en) | 2001-12-13 | 2009-05-05 | National Health Research Institutes | Indole compounds |
| UA78999C2 (en) * | 2002-06-04 | 2007-05-10 | Wyeth Corp | 1-(aminoalkyl)-3-sulfonylazaindoles as ligands of 5-hydroxytryptamine-6 |
| MXPA05008441A (es) * | 2003-02-14 | 2005-10-19 | Wyeth Corp | Derivados de heterociclil-3-sulfonilindazol o azaindazol como ligandos de 5-hidroxitriptamina-6. |
| AU2004297235A1 (en) | 2003-12-04 | 2005-06-23 | Vertex Pharmaceuticals Incorporated | Quinoxalines useful as inhibitors of protein kinases |
| PL1696920T3 (pl) | 2003-12-19 | 2015-03-31 | Plexxikon Inc | Związki i sposoby opracowywania modulatorów Ret |
| KR101298951B1 (ko) | 2004-03-30 | 2013-09-30 | 버텍스 파마슈티칼스 인코포레이티드 | Ｊａｋ 및 기타 단백질 키나제의 억제제로서 유용한아자인돌 |
| TW200611695A (en) | 2004-06-09 | 2006-04-16 | Glaxo Group Ltd | Pyrrolopyridine derivatives |
| US7498342B2 (en) | 2004-06-17 | 2009-03-03 | Plexxikon, Inc. | Compounds modulating c-kit activity |
| MX2007001399A (es) * | 2004-08-02 | 2007-04-18 | Osi Pharm Inc | Compuestos que inhiben pirrolopirimidina multi-cinasa aril-amino sustituidas. |
| MX2007007206A (es) * | 2004-12-14 | 2008-03-26 | Wyeth Corp | Uso de un agonista 5-ht6 para el tratamiento y la prevencion de trastornos neurodegenerativos. |
| US7456289B2 (en) | 2004-12-31 | 2008-11-25 | National Health Research Institutes | Anti-tumor compounds |
| US7846941B2 (en) | 2005-05-17 | 2010-12-07 | Plexxikon, Inc. | Compounds modulating c-kit and c-fms activity and uses therefor |
| TW200800959A (en) * | 2005-06-10 | 2008-01-01 | Wyeth Corp | Piperazine-piperidine antagonists and agonists of the 5-HT1a receptor |
| MX2007015772A (es) * | 2005-06-17 | 2008-02-22 | Wyeth Corp | Compuestos utiles como inhibidores de serotonina y agonistas y antagonistas de 5-ht-1a. |
| MX2007016463A (es) | 2005-06-22 | 2008-03-04 | Plexxikon Inc | Derivados de pirrolo [2,3-b] piridina como inhibidores de proteina cinasa. |
| RU2008112313A (ru) * | 2005-09-01 | 2009-10-10 | Эррэй Биофарма Инк. (Us) | Соединения ингибиторы raf и способы их применения |
| US20070129364A1 (en) * | 2005-12-07 | 2007-06-07 | Han-Qing Dong | Pyrrolopyridine kinase inhibiting compounds |
| TWI423976B (zh) | 2006-01-17 | 2014-01-21 | Vertex Pharma | 適合作為傑納斯激酶（ｊａｎｕｓ ｋｉｎａｓｅ）抑制劑之氮雜吲哚 |
| TW200811144A (en) * | 2006-06-09 | 2008-03-01 | Wyeth Corp | Crystalline forms of 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline |
| TW200808740A (en) * | 2006-06-09 | 2008-02-16 | Wyeth Corp | Succinate salts of 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline and crystalline forms thereof |
| TW200808741A (en) * | 2006-06-09 | 2008-02-16 | Wyeth Corp | 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline hydrochloric acid salts |
| WO2008063888A2 (en) | 2006-11-22 | 2008-05-29 | Plexxikon, Inc. | Compounds modulating c-fms and/or c-kit activity and uses therefor |
| US20080262228A1 (en) * | 2006-11-28 | 2008-10-23 | Wyeth | Metabolites of 5-fluoro-8- quinoline and methods of preparation and uses thereof |
| EP2815750A1 (de) | 2006-12-21 | 2014-12-24 | Vertex Pharmaceuticals Incorporated | (5-cyano-4- pyrrolo [2,3b] pyridin-3-yl) -pyrimidinderivate als Proteinkinasehemmer |
| TW200901974A (en) | 2007-01-16 | 2009-01-16 | Wyeth Corp | Compounds, compositions, and methods of making and using them |
| US20090156594A1 (en) * | 2007-05-21 | 2009-06-18 | Sgx Pharmaceuticals, Inc. | Heterocyclic kinase modulators |
| AU2008276063B2 (en) | 2007-07-17 | 2013-11-28 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| JP2011507835A (ja) | 2007-12-21 | 2011-03-10 | アンドレイ・アレクサンドロビッチ・イワシェンコ | α−アドレナリン受容体、ドーパミン、ヒスタミン、イミダゾリン及びセロトニン受容体のリガンド並びにその使用 |
| BRPI1008709B8 (pt) | 2009-04-03 | 2021-05-25 | Hoffmann La Roche | dispersão sólida, formulação, composição e comprimido compreendendo {3-[5-(4-cloro-fenil)-1h-pirrol[2,3-b]piridina-3-carbonil]-2,4-diflúor-fenil}-amida do ácido propano-1-sulfônico |
| PE20120508A1 (es) | 2009-06-17 | 2012-05-09 | Vertex Pharma | Inhibidores de la replicacion de los virus de la gripe |
| US20110112127A1 (en) | 2009-11-06 | 2011-05-12 | Plexxikon, Inc. | Compounds and methods for kinase modulation, and indications therefor |
| BR112012028055A2 (pt) * | 2010-05-06 | 2019-09-24 | Merck Sharp & Dohme | composto, uso do mesmo, composição farmacêutica, e, métodos de tratar uma doença mediada |
| WO2012083117A1 (en) | 2010-12-16 | 2012-06-21 | Vertex Pharmaceuticals Incorporated | Inhibitors of influenza viruses replication |
| MY162950A (en) | 2011-02-07 | 2017-07-31 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
| AR085279A1 (es) | 2011-02-21 | 2013-09-18 | Plexxikon Inc | Formas solidas de {3-[5-(4-cloro-fenil)-1h-pirrolo[2,3-b]piridina-3-carbonil]-2,4-difluor-fenil}-amida del acido propano-1-sulfonico |
| UA118010C2 (uk) | 2011-08-01 | 2018-11-12 | Вертекс Фармасьютікалз Інкорпорейтед | Інгібітори реплікації вірусів грипу |
| US9150570B2 (en) | 2012-05-31 | 2015-10-06 | Plexxikon Inc. | Synthesis of heterocyclic compounds |
| SG10201804026WA (en) | 2013-11-13 | 2018-06-28 | Vertex Pharma | Inhibitors of influenza viruses replication |
| SI3421468T1 (sl) | 2013-11-13 | 2021-03-31 | Vertex Pharmaceuticals Incorporated | Postopki za pripravo inhibitorjev replikacije virusov influence |
| EP3294735B8 (de) | 2015-05-13 | 2022-01-05 | Vertex Pharmaceuticals Incorporated | Hemmer der influenzavirenreplikation |
| WO2016183116A1 (en) | 2015-05-13 | 2016-11-17 | Vertex Pharmaceuticals Incorporated | Methods of preparing inhibitors of influenza viruses replication |
| WO2018064465A1 (en) | 2016-09-29 | 2018-04-05 | The Regents Of The University Of California | Compounds for increasing neural plasticity |
| AU2020229779B9 (en) | 2019-02-27 | 2025-09-18 | The Regents Of The University Of California | Azepino-indoles and other heterocycles for treating brain disorders |
| KR20230066543A (ko) * | 2020-06-10 | 2023-05-16 | 델릭스 테라퓨틱스, 인크. | 이소트립타민 사이코플라스토겐 및 이의 용도 |
| KR102347368B1 (ko) * | 2020-11-03 | 2022-01-07 | (주)케이메디켐 | 신규한 아자인돌 유도체, 이의 제조방법 및 이를 포함하는 인지기능 개선용 조성물 |
| MX2024007221A (es) | 2021-12-15 | 2024-08-27 | Delix Therapeutics Inc | Psicoplastogenos sustituidos con fenoxi y benciloxi y sus usos. |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US625923A (en) * | 1899-05-30 | Magneto-bell striker | ||
| US4654360A (en) | 1984-06-01 | 1987-03-31 | Syntex (U.S.A.) Inc. | 1,2,3-trisubstituted indoles for treatment of inflammation |
| FR2642755B1 (de) * | 1989-02-07 | 1993-11-05 | Sanofi | |
| US5132319A (en) * | 1991-03-28 | 1992-07-21 | Merck Frosst Canada, Inc. | 1-(hydroxylaminoalkyl) indole derivatives as inhibitors of leukotriene biosynthesis |
| JP2891544B2 (ja) * | 1994-06-16 | 1999-05-17 | ファイザー・インコーポレーテッド | ピラゾロおよびピロロピリジン類 |
| GB9503377D0 (en) | 1995-02-21 | 1995-04-12 | Merck Sharp & Dohme | Therapeutic agents |
| US6194410B1 (en) * | 1998-03-11 | 2001-02-27 | Hoffman-La Roche Inc. | Pyrazolopyrimidine and pyrazolines and process for preparation thereof |
| ATE330955T1 (de) * | 1998-04-28 | 2006-07-15 | Elbion Ag | Indolderivate und deren verwendung als inhibitoren der phosphodiesterase 4. |
| MXPA02001473A (es) * | 1999-08-12 | 2003-07-21 | Nps Allelix Corp | Azaindoles que tienen afinidad con el receptor de serotonina. |
| NZ522246A (en) | 2000-04-28 | 2006-01-27 | Baxter Healthcare Sa | 2-acyl indole derivatives and their use as antitumor agents |
| DE60218037T2 (de) | 2001-06-07 | 2007-08-23 | F. Hoffmann-La Roche Ag | Neue indolderivate mit affinität zum 5-ht6-rezeptor |
| JP2005527463A (ja) | 2001-08-07 | 2005-09-15 | スミスクライン ビーチャム パブリック リミテッド カンパニー | Ｃｎｓ疾患を治療するための５−ｈｔ６受容体アフィニティーを有する３−アリールスルホニル−７−ピペラジニル−インドール、−ベンゾフランおよび−ベンゾチオフェン |
| EP1497291B1 (de) | 2002-03-27 | 2006-11-22 | Glaxo Group Limited | Chinolin- und aza-indolderivate und deren verwendung als 5-ht6 liganden |
| UA78999C2 (en) * | 2002-06-04 | 2007-05-10 | Wyeth Corp | 1-(aminoalkyl)-3-sulfonylazaindoles as ligands of 5-hydroxytryptamine-6 |
-
2003
- 2003-03-06 UA UA20041210993A patent/UA78999C2/uk unknown
- 2003-05-19 TW TW092113447A patent/TW200408638A/zh unknown
- 2003-05-23 AR ARP030101811A patent/AR040047A1/es not_active Application Discontinuation
- 2003-06-03 BR BR0311591-7A patent/BR0311591A/pt not_active IP Right Cessation
- 2003-06-03 CN CNB038128721A patent/CN1315827C/zh not_active Expired - Fee Related
- 2003-06-03 PT PT03734366T patent/PT1509522E/pt unknown
- 2003-06-03 JP JP2004509681A patent/JP2005532349A/ja active Pending
- 2003-06-03 DK DK03734366T patent/DK1509522T3/da active
- 2003-06-03 KR KR10-2004-7019738A patent/KR20050013565A/ko not_active Withdrawn
- 2003-06-03 MX MXPA04011331A patent/MXPA04011331A/es active IP Right Grant
- 2003-06-03 US US10/453,010 patent/US6825212B2/en not_active Expired - Fee Related
- 2003-06-03 AT AT03734366T patent/ATE355289T1/de not_active IP Right Cessation
- 2003-06-03 DE DE60312155T patent/DE60312155T2/de not_active Expired - Fee Related
- 2003-06-03 ES ES03734366T patent/ES2282637T3/es not_active Expired - Lifetime
- 2003-06-03 SI SI200330706T patent/SI1509522T1/sl unknown
- 2003-06-03 WO PCT/US2003/017466 patent/WO2003101990A1/en not_active Ceased
- 2003-06-03 EP EP03734366A patent/EP1509522B1/de not_active Expired - Lifetime
- 2003-06-03 RU RU2004139068/04A patent/RU2315048C2/ru not_active IP Right Cessation
- 2003-06-03 AU AU2003239954A patent/AU2003239954A1/en not_active Abandoned
- 2003-06-03 IL IL16548703A patent/IL165487A0/xx unknown
- 2003-06-03 NZ NZ536959A patent/NZ536959A/en unknown
- 2003-06-03 CA CA002486191A patent/CA2486191A1/en not_active Abandoned
-
2004
- 2004-10-12 US US10/963,132 patent/US7074792B2/en not_active Expired - Fee Related
- 2004-11-03 NO NO20044763A patent/NO20044763L/no not_active Application Discontinuation
- 2004-12-02 EC EC2004005474A patent/ECSP045474A/es unknown
-
2005
- 2005-04-03 ZA ZA200500022A patent/ZA200500022B/en unknown
-
2006
- 2006-03-03 US US11/367,620 patent/US7585873B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60312155D1 (de) | 1-(aminoalkyl)-3-sulfonylazaindole als 5-hydroxytryptamin-6 liganden | |
| DE60310552D1 (de) | 1-(aminoalkyl)-3-sulfonylindol und -indazol derivative als 5-hydroxytryptamin-6 liganden | |
| ATE396191T1 (de) | Azaindolylalkylaminderivate als 5- hydroxytryptamin-6-liganden | |
| DE60207815D1 (de) | 1-aryl-oder 1-alkylsulfonylbenzazol derivate als 5-hydroxytryptamin-6 liganden | |
| DE60336811D1 (de) | Neue benzimidazolderivate | |
| DE50304983D1 (de) | Heteroaryloxy-substituierte phenylaminopyrimidine als rho-kinaseinhibitoren | |
| DE60330694D1 (de) | Pyrimidopyrimidone als kinaseinhibitoren | |
| NO20052514D0 (no) | Polysilazanholdig beleggingsopplosning | |
| IS7730A (is) | Ný fenanþrídín | |
| ZA200500435B (en) | 1-heterocyclyalkyl-3-sulfonylindole or -indazole derivatves as 5-hydroxytryptamine-6 ligands | |
| DE602004015724D1 (de) | Diazepinoindolderivate als kinaseinhibitoren | |
| DE60323892D1 (de) | Phthalocyaninverbindungen | |
| ATE335477T1 (de) | Indolylalkylamin-derivate als 5-hydroxytryptamin- 6 liganden | |
| DE602004024420D1 (de) | Chinazolinderivate als antitumormittel | |
| DE60308670D1 (de) | Substituierte indole als alpha-1 agonisten | |
| ATE354631T1 (de) | Nuancierungsmittel | |
| ATE327232T1 (de) | Heterozyklylalkylindole oder -azaindole als 5- hydroxytryptamine-6 liganden | |
| ATE421506T1 (de) | Neue benzimidazolderivate | |
| ZA200506416B (en) | Heterocyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands | |
| DK1566378T3 (da) | Isoindolinderivat | |
| ATE394372T1 (de) | G-lactamderivate als prostaglandinagonisten | |
| DE60328233D1 (de) | Sulfamatbenzothiophenderivate als steroidsulfataseinhibitoren | |
| FI20031408A0 (fi) | Säilöntälaitteisto | |
| FI20021545L (fi) | Lignaalikomplekseja | |
| PL378439A1 (pl) | Środki depigmentujące |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1509522 Country of ref document: EP |
|
| REN | Ceased due to non-payment of the annual fee |